North Star Asset Management Inc. Raises Stake in Illumina, Inc. $ILMN

North Star Asset Management Inc. boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 26.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,697 shares of the life sciences company’s stock after buying an additional 38,220 shares during the quarter. North Star Asset Management Inc.’s holdings in Illumina were worth $24,094,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ILMN. Elyxium Wealth LLC purchased a new stake in Illumina in the fourth quarter worth approximately $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina in the fourth quarter worth approximately $26,000. Creative Capital Management Investments LLC boosted its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new stake in Illumina in the fourth quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina in the fourth quarter worth approximately $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $144.41 on Friday. The firm has a market cap of $21.85 billion, a PE ratio of 26.26, a price-to-earnings-growth ratio of 2.39 and a beta of 1.42. Illumina, Inc. has a fifty-two week low of $78.55 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The business has a 50 day moving average price of $130.45 and a 200-day moving average price of $130.91.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on ILMN shares. Citigroup upped their target price on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Guggenheim upped their target price on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. UBS Group reissued a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $137.75.

Insider Buying and Selling

In related news, Director Keith A. Meister sold 104,393 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the transaction, the director owned 3,500,048 shares in the company, valued at $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 330,160 shares of company stock valued at $48,028,308. Insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.